Clinical trial · Interventional
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
A Prospective Study of Hypofractionated Radiotherapy for Thymic Epithelial Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors. The main questions it aims to answer are: * Does Hypofractionated radiotherapy provide better results? * Can hypofractionated radiotherapy reduce toxic and side effects compared with conventional radiotherapy? Researchers will compare the efficacy and safety of hypofractionated radiotherapy after thymic tumor surgery. Participants will: * Receive hypofractionated radiotherapy or conventional radiotherapy * Visit the hospital regularly once every 12 weeks for checkups and tests
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thymic Cancer | — | UNRESOLVED | — |
| Thymic Epithelial Tumor | Thymus Epithelial Neoplasm | ALIAS | 0.90 |
| Thymoma | Thymoma | ONTOLOGY_EXACT | 0.98 |
| Thymoma and Thymic Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypofractionated Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Hypofractionated Radiotherapy
- description
- R0 resection: 42-48 Gy/14-16f or 40-44 Gy or 10-11f,40 Gy/8f R1 resection: 48-51 Gy/16-17f or 44-48 Gy/11-12f or 40-45 Gy/8-9f R2 resection: 51-60 Gy/17-20f or 48-56 Gy/12-14f or 45 -60Gy/9-12f
- interventionNames
- Radiation: Hypofractionated Radiation Therapy
- type
- NO_INTERVENTION
- label
- Conventional Radiotherapy
- description
- R0 resection: 45-50Gy/20-25f R1 resection: 54-56Gy/25-28f R2 resection: 60-70Gy/30-35f
Primary outcomes (1)
- measure
- 3-year PFS
- timeFrame
- The patients were followed up for 3 years from enrollment to disease progression or death.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients must provide written informed consent. 2. 18 years old ≤ age \<75 years old. 3. Thymoma confirmed by pathology: type A, type AB, type B1, type B2, type B3. Thymic carcinoma. Patients with previous thymectomy were required to have complete surgical related data. 4. Masaoka⁃Koga ⁃ stage Ⅰ-Ⅲ 5. ECOG performance status 0-2. 6. Expected survival time \> 1 year. 7. Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative. 8. Patients who are not lactating. 9. Sufficient bone marrow reserve and good function of important organs. Exclusion Criteria: 1. patients with prior thoracic radiotherapy; 2. diseases not suitable for radiotherapy, such as recent myocardial infarction, active congestive heart failure; 3. Uncontrolled infectious disease or other serious medical or mental illness that may interfere with care 4. Patients with other malignant tumors that are not under stable control; 5. Known history of mental illness, substance abuse, alcohol or drug abuse. 6. Other conditions deemed unsuitable for enrollment by the attending physician.
References
Publications (0)
Data not yet available